



TEXAS STATE BOARD OF PHARMACY

1801 Congress Ave, Room 4.300
Austin, Texas

Tuesday, February 3, 2026

MINUTES¹

BOARD BUSINESS MEETING

Tuesday, February 3, 2026

President Julie Spier, R.Ph., called the meeting to order at 9:00 a.m. Other Board Members present were Vice President Donna Montemayor, R.Ph.; Treasurer Donnie Lewis, R.Ph.; Rick Fernandez, R.Ph.; Heisha Freeman; Stacy Hightower, Ph.T.R.; Randy Martin, Pharm.D., R.Ph.; Donna Montemayor, R.Ph.; Ian Shaw; Suzette Tijerina, R.Ph.; Rick Tisch; and Jenny Downing Yoakum, R.Ph.

Staff present were Daniel Carroll, Pharm.D., R.Ph., Executive Director/Secretary; Megan Holloway, General Counsel; Caroline Hotchkiss, Director of Enforcement; John Griffith, Litigation Counsel; Ann Driscoll, Director of Operations; Ruben Leal, Finance Team Supervisor; David Meryman, Ph.T.R., Prescription Monitoring Program Director; Eamon Briggs, Deputy General Counsel; Sean Leeper, Government Relations Specialist; and Lily Moreno, Executive Assistant.

A. Announcements

President Spier made general announcements, including concerning continuing education credit for attending the Board Meeting, and reviewed the meeting procedures.

B. Discussion and Approval of Minutes of Previous Meetings (Item B)

Following discussion, the motion was made by Mr. Shaw to approve the minutes of the Board Member Training Session held November 3, 2025, and the minutes of the Board Business Meeting held November 4, 2025. The motion was seconded by Mr. Lewis and passed unanimously.

¹See agenda and corresponding attachments for supporting materials.

C. Discussion of and Possible Action Regarding Rules

Final Adoption of Rules

- Rules Concerning Operational Standards (§§291.33 and 291.104) (Items C.1.1.1 and C.1.1.2)

Mr. Griffith explained that the Board voted to propose the amendments to §§291.33 and 291.104 during its November 4, 2025, meeting. The proposed amendments were published in the December 26, 2025, issue of the *Texas Register*.

Mr. Griffith directed the Board's attention to amendments to §§291.33 and 291.104 and explained that the proposed amendments allow for written information reinforcing patient counseling to be provided electronically unless requested in a hard-copy format and remove the requirement to document the request.

Written comments were received from the Texas Association of Health Plans in support of the amendments.

Following discussion and review of the Preamble and Order Adopting Rules, the motion was made by Mr. Fernandez to approve for adoption, by Board Order, the amendments to §§291.33 and 291.104, as presented. The motion was seconded by Mr. Tisch and passed unanimously.

- Rules Concerning Continuing Education Requirements (§§295.8 and 297.8) (Items C.1.2.1 and C.1.2.2)

Mr. Griffith explained that the Board voted to propose the amendments to §§295.8 and 297.8 during its November 4, 2025, meeting. The proposed amendments were published in the December 26, 2025, issue of the *Texas Register* and no comments were received.

Mr. Griffith directed the Board's attention to amendments to §§295.8 and 297.8 and explained that the proposed amendments establish an electronic continuing education tracking system in accordance with Senate Bill 912 of the 89th Legislature, R.S., update continuing education programs in preparation for the statutory continuing education tracking system, specify that record retention requirements apply to all required courses, and make grammatical corrections.

Following discussion and review of the Preamble and Order Adopting Rules, the motion was made by Mr. Tisch to approve for adoption, by Board Order, the amendments to §§295.8 and 297.8, as presented. The motion was seconded by Mr. Shaw and passed unanimously.

- Rules Concerning Pharmacies Compounding Sterile Preparations (§291.133) (Item C.1.3)

Mr. Briggs explained that the Board voted to propose the amendments to §291.133 during its June 17, 2025, meeting. The proposed amendments were published in the October 3, 2025, issue of the *Texas Register*.

Mr. Briggs directed the Board's attention to amendments to §291.133 and explained that the proposed amendments update the personnel, environment, compounding process, cleaning and disinfecting, beyond-use dating, cleansing and garbing, environmental testing, sterility testing, recall procedure, and recordkeeping requirements for pharmacies compounding sterile preparations.

Written comments were received from the following:

- Alliance for Pharmacy Compounding, in support of some of the amendments, expressing concern with some of the amendments, and suggesting changes;
- Brad Jordan, Ph.D., with Eli Lilly, in support of some of the amendments, expressing concern with some of the amendments, and suggesting changes;
- Dee Eid, R.Ph., with Empower Pharmacy, expressing concern with some of the amendments, suggesting the Board send the rule back to the Compounding Rules Advisory Group – Sterile Subcommittee, and suggesting changes;
- Stephen Snow with Bendin Sumrall & Ladner, LLC, expressing concern with the estimated costs;
- Jasper Lovoi, R.Ph., with The Woodlands Compounding Pharmacy, in support of some of the amendments and expressing concern with some of the amendments;
- Jim Hrcir, R.Ph., with Las Colinas Pharmacy Compounding & Wellness, expressing concern with some of the amendments and suggesting changes; and
- John Daniel, R.Ph., suggesting changes.

Oral comments were received from the following:

- Mr. Snow, reiterating his written comments;
- Mr. Hrcir, reiterating his written comments;
- Jonathan Head, Pharm.D., R.Ph., expressing concern with some of the amendments and suggesting changes;
- Frank Kratofil, R.Ph., with Empower Pharmacy, reiterating his organization's written comments; and
- Suzanne Henry, with Texas Society of Health-System Pharmacy, in opposition to the proposed amendments and expressing concerns.

President Spier recessed the meeting at 9:54 a.m.
Mr. Leal left the meeting during the break.
President Spier reconvened the meeting at 10:17 a.m.

Following discussion and review of the Preamble and Order Adopting Rules, the motion was made by Mr. Martin to approve for adoption, by Board Order, the amendments to §291.133, with the changes set forth in the discussion. The motion was seconded by Mr. Lewis and passed unanimously.

Proposal of Rules

- Rules Concerning Telehealth Services Provided by a Pharmacist (§291.13) (Item C.2.1)

Mr. Griffith directed the Board's attention to suggested new rule language concerning telehealth services provided by a pharmacist. He explained that the new rule would establish the documentation and retention requirements regarding a patient's consent to treatment, data collection, and data sharing for telehealth services provided by a pharmacist, in accordance with House Bill 1700 of the 89th Legislature, R.S.

Following discussion, the motion was made by Ms. Montemayor to approve for proposal amendments to §291.13, as presented. The motion was seconded by Mr. Lewis and passed unanimously.

Rule Review

Mr. Griffith directed the Board's attention to the Board Rule Review Plan for FY2026-FY2029 (Item C.3).

- For Adoption
 - Chapter 291 Concerning Pharmacies (Nuclear Pharmacy (Class B)) (§§291.51 – 291.55) (Item C.3.1.1)
 - Chapter 309 Concerning Substitution of Drug Products (§§309.1 – 309.8) (Item C.3.1.2)

Following discussion, in accordance with Government Code §2001.039, the motion was made by Mr. Martin to approve for adoption, as presented, the review of Chapter 291 Concerning Pharmacies (Nuclear Pharmacy (Class B)) (§§291.51 – 291.55) and Chapter 309 Concerning Substitution of Drug Products (§§309.1 – 309.8). The motion was seconded by Mr. Lewis and passed unanimously.

**D. Discussion of and Possible Action Concerning Reports of Committees/
Task Forces**

- Report on Prescription Monitoring Program (PMP) Advisory Committee (Item D.1)

Dr. Carroll reported that the PMP Advisory Committee attempted to meet on December 19, 2025, however, due to lack of a quorum the meeting was canceled and rescheduled for February 27, 2026.

- Report on Interagency Prescription Monitoring Program Work Group (Item D.2)

Dr. Carroll reported that the Interagency Prescription Monitoring Program Work Group held a meeting on January 21, 2026, to consider proposals from the PMP Advisory Committee regarding the website display of PMP data. He reported that there were no objections to the PMP Advisory Committee proposals.

**E. Discussion of and Possible Action Concerning the Following Reports and
Discussions**

- Financial Report
 - Review of FY2026 First Quarter Expenditures (Item E.1.1)

Ms. Driscoll reviewed the expenditures for the first quarter of FY2026 (September 1, 2025 – November 30, 2025) for the Board.
 - Review of Board Member Travel Budget (Item E.1.2)

Ms. Driscoll reviewed the Board Member Travel Budget for the first quarter of FY2026 (September 1, 2025 – November 30, 2025).
 - Consideration of Material Changes to Contracts for Goods and Services Awarded Under Chapter 2155 of Texas Government Code (Item E.1.3)

Ms. Driscoll reported that there were no material changes to contracts for goods and services the first quarter of FY2026 (September 1, 2025 – November 30, 2025).
- Review and Approval of FY2027-2031 Strategic Plan Issue Statements (Item E.3)

Dr. Carroll directed the Board's attention to the FY2027-FY2031 Strategic Plan Timeline and the issue statements from the internal/external assessment.

Following discussion, a motion was made by Mr. Tisch to approve the issue statements for the FY2027-FY2031 Strategic Plan, as presented. The motion was seconded by Mr. Shaw and passed unanimously.

- Review and Approval of TSBP FY2025 Annual Report (Item F.4)

Dr. Carroll directed the Board's attention to a draft of the TSBP FY2025 Annual Report.

Following review, a motion was made by Mr. Martin to approve the TSBP FY2025 Annual Report, as presented. The motion was seconded by Mr. Lewis and passed unanimously.

- Report on Prescription Monitoring Program (Item E.5)

Mr. Meryman reviewed the Prescription Monitoring Program (PMP) data for the first quarter of FY2026 (September 1, 2025 – November 30, 2025). He also reported that a new license verification tool was implemented to assist Board staff with verifying that PMP users maintain credentials to access the PMP system.

- Report on Appeals from State Office of Administrative Hearing Cases and Other Court Actions (Item E.6)

Ms. Holloway provided an update on the matter concerning a pharmacist who has an agreed board order, entered in February 2017, and had notified Board staff about an order of non-disclosure relating to the underlying conduct, and following which the petitioner had filed suit against the Board in Harris County, Texas. On January 8, 2026, the Office of the Attorney General's motion to transfer the venue to Travis County was granted.

- Update on Legislation Passed During the 89th Texas Legislative Session that has an Impact on TSBP and/or the Practice of Pharmacy (Item E.7)

Mr. Leeper directed the Board's attention to a chart showing legislation Board staff tracked that has an impact on TSBP and/or the practice of pharmacy. He reviewed the updated items on the chart for the Board.

- Discussion Concerning Applicant Examination Requirement Timeline (Item E.8)

President Spier reported that at some recent NABP District meetings, the topic of allowing applicants for pharmacist licensure to take the Multistate Pharmacy Jurisprudence Examination (MPJE) after their third year in pharmacy school, before internships, was discussed to decrease post-graduation requirements as they prepare for and take the NAPLEX.

President Spier noted that if the Board moves forward with allowing applicants to take the MPJE prior to graduation, rulemaking would be required and it would impact how the Board's Licensing team processes the applications.

President Spier recognized Misty Anderson, Director of Licensing, who provided information about how the change would impact the Licensing workflow and the application process.

Following discussion, the Board directed Board staff to bring back potential rule amendments for review.

- Discussion Concerning Petition for Six-Year Cap and Inactive Status Option (Item E.9)

Ms. Holloway directed the Board's attention to a petition received from Jeanne Lee, an applicant for pharmacist licensure who currently resides in South Korea. Ms. Holloway explained that Ms. Lee requested that the Board adopt a six-year cap from graduation for pharmacist licensure completion and an inactive status option for licensed pharmacists medically unable to practice. Ms. Holloway recommended that the Board deny the petition as there is currently an inactive license status that does not require the licensee to disclose medical information and a six-year cap would prevent any pharmacist who graduated more than six years prior from being licensed by examination in Texas. She explained that the six-year cap could also negatively affect Ms. Lee if she did not return to the United States and complete her application process within six years of her graduation.

Following discussion, a motion was made by Ms. Freeman to deny the petition. The motion was seconded by Mr. Shaw and passed unanimously.

F. Consideration of and Possible Action Concerning Enforcement Reports

- Report on Complaints Closed and Dismissed During the Previous Quarter (Item F.1)

Ms. Hotchkiss reported on complaints dismissed and closed during the first quarter of FY2026 (September 1, 2025 – November 30, 2025). The report also included a comparison of complaints closed with disciplinary orders to those closed without disciplinary orders and a comparison of quarterly averages for FY2026 to the quarterly averages for FY2025, as well as percentage change from FY2025 to FY2026.

- Report on Status of Active/Pending Complaints (Item F.2)

Ms. Hotchkiss reviewed the *Report on Status of Active/Pending Complaints* for the Board.

G. Disciplinary Orders

- Report on Agreed Board Orders and Board Orders Entered by Executive Director (Item G.1)
 - The Board reviewed 10 Agreed Board Orders concerning pharmacy technicians and pharmacy technician trainees that had been entered by the Executive Director on behalf of the Board, in accordance with the Board's directives, during the period from November 19, 2025, through January 27, 2026.
 - The Board reviewed 3 Agreed Board Orders concerning pharmacists that had been entered by the Executive Director on behalf of the Board, in accordance with the Board's directives, during the period from November 13, 2025, through December 10, 2025.
 - The Board reviewed 4 Board Orders concerning pharmacies that had been entered by the Executive Director on behalf of the Board, in accordance with the Board's directives, during the period from January 8, 2026, through January 27, 2026.
 - The Board reviewed 1 Confidential Agreed Board Order concerning a pharmacist that had been entered by the Executive Director on behalf of the Board, in accordance with the Board's directives, on January 27, 2026.
- Discussion of and Action on Proposed Agreed Board Orders, Proposed Default Board Orders, and Proposed Remedial Plans (Items G.2 and G.3)

The Board reviewed the alleged violations, as well as the recommended sanctions for each of the following:

- 20 proposed Agreed Board Orders concerning pharmacy technicians and pharmacy technician trainees who appeared for an Informal Conference;
- 6 proposed Default Board Orders concerning pharmacy technicians and pharmacy technician trainees who did not appear for an Informal Conference;
- 15 proposed Agreed Board Orders concerning pharmacies and pharmacists (Alternative Resolutions);
- 23 proposed Agreed Board Orders concerning pharmacies and pharmacists who appeared for an Informal Conference;

- 7 proposed Confidential Agreed Board Orders concerning pharmacists who appeared for an Informal Conference;
- 9 proposed Remedial Plans concerning pharmacies and pharmacists (Alternative Resolutions); and
- 3 proposed Remedial Plans concerning pharmacists who appeared for an Informal Conference.

The motion was made by Mr. Shaw to approve the proposed Disciplinary Orders and Remedial Plans, as presented. The motion was seconded by Ms. Montemayor, and the motion passed as follows:

No.	Name	T, I, R, or P*	ABO, DBO, or RP**	Order # or Plan #	Board Vote (Yes-No-Abstain)	Abstained Board Members
1	Mary Lee Fuller	T	ABO	2024-06885	8-0-2	Lewis, Tisch
2	Stephanie Lynn Gest	T	ABO	2025-5486	8-0-2	Lewis, Tisch
3	Abigail Mariah Erevia	T	ABO	2025-04171	8-0-2	Martin, Yoakum
4	Niloufar Seifi	T	ABO	2024-06590	8-0-2	Martin, Yoakum
5	Taeja A. Young	T	ABO	2025-01401	8-0-2	Martin, Yoakum
6	Lasatria Austin	T	ABO	2025-04755	8-0-2	Montemayor, Shaw
7	Mercedes DeUnca Jones	T	ABO	2025-03937	8-0-2	Montemayor, Shaw
8	David Coby Munoz	T	ABO	2025-01451	8-0-2	Montemayor, Shaw
9	David Otieno	T	ABO	2025-02428	8-0-2	Montemayor, Shaw
10	Cynthia Pimentel	T	ABO	2025-04021	8-0-2	Montemayor, Shaw
11	Shawn Rayford	T	ABO	2025-04903	8-0-2	Montemayor, Shaw
12	Crystal Salas	T	ABO	2025-05252	8-0-2	Montemayor, Shaw
13	Sammie Joe Washington Jr.	T	ABO	2025-02493	8-0-2	Montemayor, Shaw
14	Tazmikia Webber	T	ABO	2025-04330	8-0-2	Montemayor, Shaw
15	Robert Michael Zamora	T	ABO	2025-05099	8-0-2	Montemayor, Shaw
16	Savannah A. Echhade	T	ABO	2025-05766	8-0-2	Fernandez, Tijerina
17	Veronica Elizabeth Grable	T	ABO	2025-05651	8-0-2	Fernandez, Tijerina
18	Lashawn D. Johnson	T	ABO	2026-00660	8-0-2	Fernandez, Tijerina
19	Denicea Lavonne Weaver-Mial	T	ABO	2025-05463	8-0-2	Fernandez, Tijerina
20	Tra'avia Wilson	T	ABO	2026-00919	9-0-1	Montemayor
21	Jacqueline Monique Nicholson	T	DBO	2026-00100	8-0-2	Montemayor, Shaw
22	Kelly Marie Zickafoose	T	DBO	2025-05607	8-0-2	Montemayor, Shaw
23	Victor Chima Ogwo	T	DBO	2025-03414	8-0-2	Montemayor, Shaw
24	Elsa Marie Corpus	T	DBO	2025-03914	9-0-1	Montemayor
25	Chance Landon Edward Ross	T	DBO	2025-01313	9-0-1	Montemayor
26	Edward Salinas	T	DBO	2026-00262	9-0-1	Montemayor

*Technician or Technician Trainee (T), Pharmacist Intern (I), Pharmacist (R), and Pharmacy (P)

**Agreed Board Order (ABO), Default Board Order (DBO), and Remedial Plan (RP)

TSBP Board Business Meeting

Minutes/February 3, 2026

Page 10

No.	Name	T, I, R, or P*	ABO, DBO, or RP**	Order # or Plan #	Board Vote (Yes-No-Abstain)	Abstained Board Members
27	Aisha Nazareth Camet	R	ABO	2026-00593	10-0-0	-
28	CVS/pharmacy #1020	P	ABO	2025-01412	9-0-1	Tijerina
29	CVS/pharmacy #6978	P	ABO	2025-02781	9-0-1	Tijerina
30	James Michael Varnell	R	ABO	2026-00360	9-0-1	Tijerina
31	CVS/pharmacy #7481	P	ABO	2024-06543	9-0-1	Tijerina
32	CVS/pharmacy #10221	P	ABO	2025-03170	9-0-1	Tijerina
33	CVS/pharmacy #10598	P	ABO	2025-00584	9-0-1	Tijerina
34	H.E.B. Pharmacy #656	P	ABO	2024-06129	9-0-1	Montemayor
35	Optum Infusion Services 305 LLC	P	ABO	2025-05059	10-0-0	-
36	Waco Endoscopy Center LLC	P	ABO	2025-04802	10-0-0	-
37	Walgreens #06660	P	ABO	2025-02020	9-0-1	Fernandez
38	Duan Van Nguyen	R	ABO	2025-04499	9-0-1	Fernandez
39	Walgreens #09291	P	ABO	2025-02707	9-0-1	Fernandez
40	Walmart Pharmacy 10-440	P	ABO	2024-07188	10-0-0	-
41	Walmart Pharmacy 10-3773	P	ABO	2025-02013	10-0-0	-
42	Zichang Liu	R	ABO	2025-03557	8-0-2	Lewis, Tijerina
43	Okwudili T. Okpara	R	ABO	2025-01785	8-0-2	Lewis, Tisch
44	Prudential Pharmacy, Inc	P	ABO	2025-01623	9-0-1	Lewis
45	Eric Todd Ellison	R	ABO	2025-05476	8-0-2	Martin, Yoakum
46	Omar Espericueta	R	ABO	2025-04946	8-0-2	Martin, Yoakum
47	Martin James Farrell	R	ABO	2025-05111	8-0-2	Martin, Yoakum
48	Victoria Renee Guerra	R	ABO	2025-04945	8-0-2	Martin, Yoakum
49	Kristine Miller Isaacson	R	ABO	2025-02511	8-0-2	Martin, Yoakum
50	Jody Neal Meigs	R	ABO	2025-05474	8-0-2	Martin, Yoakum
51	Strive Pharmacy LLC	P	ABO	2025-02040	8-0-2	Martin, Yoakum
52	Anthony Clay Coleman	R	ABO	2026-00367	8-0-2	Fernandez, Tijerina
53	Anthony Dwayne Essett	R	ABO	2026-00657	8-0-2	Fernandez, Tijerina
54	Femi Eze Felix-Ukwu	R	ABO	2024-02257	8-0-2	Fernandez, Tijerina
55	HEB Pharmacy #333	P	ABO	2024-03378	7-0-3	Fernandez, Montemayor, Tijerina
56	Krishna Jatin Patel	R	ABO	2025-03384	7-0-3	Fernandez, Montemayor, Tijerina
57	Joshua Pharmacy	P	ABO	2024-07015	8-0-2	Fernandez, Tijerina
58	Jonathan Paul Lipe	R	ABO	2025-00969	8-0-2	Fernandez, Tijerina
59	Kelvin Kenyoru	R	ABO	2024-06491	8-0-2	Fernandez, Tijerina
60	Jesus Christian Ortega	R	ABO	2025-02253	9-0-1	Tijerina
61	Catherine Larmley Baah-Sarfo	R	ABO	2025-06180	9-0-1	Montemayor

*Technician or Technician Trainee (T), Pharmacist Intern (I), Pharmacist (R), and Pharmacy (P)

**Agreed Board Order (ABO), Default Board Order (DBO), and Remedial Plan (RP)

No.	Name	T, I, R, or P*	ABO, DBO, or RP**	Order # or Plan #	Board Vote (Yes-No- Abstain)	Abstained Board Members
62	Mohamed Mahmoud Awad Bassiouni	R	ABO	2026-01000	9-0-1	Montemayor
63	Nelson Juan Rodriguez Menchaca	R	ABO	2025-06765	9-0-1	Montemayor
64	Jason Anthony Zucha	R	ABO	2025-06181	9-0-1	Montemayor
65	<i>Confidential</i>	R	ABO	2025-02177	8-0-2	Lewis, Montemayor
66	<i>Confidential</i>	R	ABO	2025-06010	8-0-2	Martin, Yoakum
67	<i>Confidential</i>	R	ABO	2025-05590	8-0-2	Fernandez, Tijerina
68	<i>Confidential</i>	R	ABO	2025-05853	8-0-2	Fernandez, Tijerina
69	<i>Confidential</i>	R	ABO	2025-06052	8-0-2	Fernandez, Tijerina
70	<i>Confidential</i>	R	ABO	2025-05444	8-0-2	Fernandez, Tijerina
71	<i>Confidential</i>	R	ABO	2025-06168	8-0-2	Fernandez, Tijerina
72	Mark Salce Carrillo	R	RP	2025-03469	10-0-0	-
73	Naaman Garza	R	RP	2025-03839	10-0-0	-
74	Ebram Khalil	R	RP	2025-04587	10-0-0	-
75	An Nguyen	R	RP	2025-03827	10-0-0	-
76	Ifeoma Eucharía Nwogbo	R	RP	2025-04251	10-0-0	-
77	Shyam Dharmendrakumar Patel	R	RP	2025-04956	10-0-0	-
78	San Diego Pharmacy	P	RP	2024-04700	10-0-0	-
79	Lisa Ann Walker	P	RP	2025-05394	10-0-0	-
80	Jonathan Marcus Wilson	R	RP	2026-00532	10-0-0	-
81	Sheraz Ahmed Khan	R	RP	2025-03919	8-0-2	Martin, Yoakum
82	Daniel Eduardo Alonso	R	RP	2025-03869	8-0-2	Fernandez, Tijerina
83	Victoria Montgomery White	R	RP	2025-05287	9-0-1	Montemayor

*Technician or Technician Trainee (T), Pharmacist Intern (I), Pharmacist (R), and Pharmacy (P)
 **Agreed Board Order (ABO), Default Board Order (DBO), and Remedial Plan (RP)

President Spier recessed the meeting at 11:20 a.m.
President Spier reconvened the meeting at 1:00 p.m.

E. Discussion of and Possible Action Concerning the Following Reports and Discussions, continued

- Professional Recovery Network (PRN)
 - Ms. Hotchkiss discussed performance measures regarding the number of individuals participating in the peer assistance program for the first quarter of FY2026 (September 1, 2025 – November 30, 2025). (Item E.2.1)

- President Spier recognized PRN Program Director Raquel Leal, LPC. Ms. Leal directed the Board's attention to the PRN expense report for the first quarter of FY2026 (September 1, 2025 – November 30, 2025) and reviewed PRN activities for the Board. (Item E.2.2)

H. Miscellaneous

- Items to be Placed on Agenda for May 5, 2026, Board Meeting (Item H.1)

Ms. Freeman requested a discussion concerning requiring a notification from pharmacies to prescribers if a prescription is unable to be filled.

President Spier requested Board members to submit any additional items for the May 5, 2026, Board meeting to staff.


- Discussion of and Possible Action on Upcoming Conferences and Events (Item H.2)

President Spier reviewed upcoming meetings and conferences.


Mr. Shaw made the motion to adjourn the meeting. The motion was seconded by Mr. Martin and passed unanimously.

President Spier adjourned the meeting at 1:07 p.m.

APPROVED:



Julie Spier, R.Ph.
President



Daniel Carroll, Pharm.D., R.Ph.
Executive Director/Secretary

May 5, 2026